Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-1325
- Development stage
- Phase 1
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
mRNA-1325 is an experimental mRNA-based vaccine developed by Moderna for the prevention of Zika virus infection. It was the first Zika vaccine candidate to enter clinical trials using Moderna's messenger RNA technology, which involves encoding viral antigens—specifically the pre-membrane (prM) and envelope (E) proteins of the Zika virus—within a lipid nanoparticle (LNP) delivery system. The development of mRNA-1325 was accelerated by significant non-dilutive funding from the Biomedical Advanced Research and Development Authority (BARDA) and the Defense Advanced Research Projects Agency (DARPA) in response to the 2015-2016 Zika outbreak. Although it successfully completed a Phase 1 dose-ranging study (NCT02964390) in healthy adults, Moderna subsequently prioritized a second-generation Zika vaccine candidate, mRNA-1893, which demonstrated a more robust profile.
- Other names
- mRNA 1325mRNA1325mRNA-1325
02
Targets
ZIKV E (Zika virus envelope protein)prM (Zika virus precursor membrane protein)
Beyond the preview
Go deeper on mRNA-1325.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-1325.